The Filing Desk

MediWound vs Relay Therapeutics

MediWound MDWD · Relay Therapeutics RLAY · Biotechnology

MediWound reported revenue of $17 million in fiscal 2025, about the same as Relay Therapeutics' $15 million in fiscal 2025. MediWound's revenue fell 16.1% in its latest year, and Relay Therapeutics' grew 53.4%. MediWound had an operating margin of -149.0%, against -1971.6% at Relay Therapeutics. Free cash flow was −$22 million at MediWound and −$236 million at Relay Therapeutics.

Side by side

MediWoundRelay Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$17M$15M
Revenue growth−16.1%53.4%
Revenue growth a year, last 5 years−4.9%−28.5%
Gross margin19.2%—
Operating margin−149.0%−1,971.6%
Net margin−140.8%−1,800.6%
Free cash flow−$22M−$236M
Free cash flow margin−127.5%−1,536.1%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count14.2%20.1%
Last close$13.54$15.91
P/E at the last close——
Insider trades, last 12 months—sold $127.9 million
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
MediWoundRelay Therapeutics
Operating margin
Percent of revenue
MediWoundRelay Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
MediWoundRelay Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the MediWound and Relay Therapeutics pages.